Loading
Latest filing published 18 Aug 2026 for Avalo Therapeutics, Inc., €537k. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Christopher Ryan Sullivan is a declared insider of Avalo Therapeutics, Inc., with filings sourced from SEC (Form 4). We count 3 filings; the first trade dates from 17 August 2026 and the latest from 18 August 2026.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
The record was last updated on 18 August 2026 with a transaction (€537k) in Avalo Therapeutics, Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations